Neoadjuvant hepatic arterial infusion chemotherapy
Showing 1 - 25 of >10,000
Recurrent Liver Cancer After Liver Transplantation Trial (Hepatic arterial infusion chemo + Atezolizumab and bevacizumab)
Not yet recruiting
- Recurrent Liver Cancer After Liver Transplantation
- Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
- (no location specified)
Apr 17, 2023
HepaSphere Transarterial Chemoembolization Combined With Hepatic
Not yet recruiting
- Colorectal Liver Metastases (CRCLM)
- DEB-TACE plus HAIC
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
May 25, 2023
HepaSphere Drug-eluting Bead Transarterial Chemoembolization
Recruiting
- Advanced Hepatocellular Carcinoma (HCC)
- DEB-TACE plus HAIC or HAIC alone
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
May 19, 2023
Thrombocytopenia, Hepatocellular Carcinoma Trial in Guangzhou (Avatrombopag)
Not yet recruiting
- Thrombocytopenia
- Hepatocellular Carcinoma
-
Guangzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangzhou Medical University
Aug 17, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Atezolizumab, Bevacizumab, HAIC with FOLFOX)
Recruiting
- Hepatocellular Carcinoma
- Atezolizumab
- +2 more
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
May 24, 2023
Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer Trial in Beijing (Fruquintinib, Hepatic Arterial Infusion
Recruiting
- Advanced Colorectal Carcinoma
- Liver Metastasis Colon Cancer
- Fruquintinib
- Hepatic Arterial Infusion Chemotherapy
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Jun 1, 2022
Hepatocellular Carcinoma Trial (HAIC(FOLFOX), Oxaliplatin, Leucovorin)
Not yet recruiting
- Hepatocellular Carcinoma
- HAIC(FOLFOX)
- +5 more
- (no location specified)
Aug 16, 2022
Hepatocellular Carcinoma Trial in Guangzhou (HAIC, Zoledronic acid)
Recruiting
- Hepatocellular Carcinoma
- HAIC
- Zoledronic acid
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
May 10, 2023
Colorectal Liver Metastases Trial in Beijing (Tislelizumab, Regorafenib, HAIC)
Recruiting
- Colorectal Liver Metastases
- Tislelizumab
- +2 more
-
Beijing, Beijing, China
- +1 more
May 25, 2023
Locally Advanced Gastric Carcinoma Trial in Hanzhou (Oxaliplatin by arterial infusion plus S-1, SOX neoadjuvant, gastrectomy
Not yet recruiting
- Locally Advanced Gastric Carcinoma
- Oxaliplatin by arterial infusion plus S-1
- +3 more
-
Hanzhou, Zhejiang, ChinaGastrointestinal Department of Second Affiliated Hospital of Zhe
Oct 20, 2022
Colorectal Liver Metastasis Trial in Shanghai (HAIC-FOLFOX combined with Sintilimab and Regorafenib)
Recruiting
- Colorectal Liver Metastasis
- HAIC-FOLFOX combined with Sintilimab and Regorafenib
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 1, 2023
Hepatocellular Carcinoma Trial in Wuhan (Nocardia rubra cell wall skeleton, Hepatic arterial infusion chemo, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma
- Nocardia rubra cell wall skeleton
- +3 more
-
Wuhan, Hubei, ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College,
Sep 5, 2022
Hepatocellular Carcinoma, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemo Trial in Chongqing (Esketamine,
Not yet recruiting
- Hepatocellular Carcinoma
- +3 more
-
Chongqing, Chongqing, ChinaThe Second Affiliated Hospital, Chongqing Medical University
Jun 9, 2022
Uveal Melanoma, Metastatic Cutaneous Melanoma Trial (Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2)
Not yet recruiting
- Uveal Melanoma
- Metastatic Cutaneous Melanoma
- Autologous Tumor Infiltrating Lymphocytes
- +2 more
- (no location specified)
Jun 5, 2023
Hepatocellular Carcinoma, Chemo Effect, Chemotherapeutic Toxicity Trial in Guangzhou (Oxaliplatin,calcium folinic acid,
Recruiting
- Hepatocellular Carcinoma
- +2 more
- Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
- +4 more
-
Guangzhou, Guangdong, ChinaSUN Yat-sen University Cancer Center
Sep 11, 2023
Hepatocellular Carcinoma Trial in Jinan (Camrelizumab)
Recruiting
- Hepatocellular Carcinoma
-
Jinan, Shandong, ChinaShandong Cancer Hospital and Institute
Nov 16, 2022
Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma Trial (Autologous Tumor Infiltrating Lymphocytes, Melphalan,
Not yet recruiting
- Metastatic Uveal Melanoma
- Metastatic Cutaneous Melanoma
- Autologous Tumor Infiltrating Lymphocytes
- +2 more
- (no location specified)
Oct 14, 2022
Macrotrabecular Massive Hepatocellular Carcinoma Trial in Wuhan (HAIC, Camrelizumab plus Apatinib)
Recruiting
- Macrotrabecular Massive Hepatocellular Carcinoma
- HAIC
- Camrelizumab plus Apatinib
-
Wuhan, Hubei, ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College,
May 1, 2023
Intrahepatic Cholangiocarcinoma Trial in GuangZhou (HAIC Combined with Tislelizumab and Apatinib)
Recruiting
- Intrahepatic Cholangiocarcinoma
- HAIC Combined with Tislelizumab and Apatinib
-
GuangZhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 4, 2022
Hepatic Metastases, Colon Cancer, Rectal Cancer Trial in United States (Bevacizumab HAI plus systemic chemo, HAI plus systemic
Active, not recruiting
- Hepatic Metastases
- +2 more
- Bevacizumab HAI plus systemic chemotherapy
- HAI plus systemic chemotherapy
-
Basking Ridge, New Jersey
- +4 more
Apr 26, 2022
Colorectal Cancer, Metastatic Cancer Trial in New Brunswick, New York (FOLFOX regimen, dexamethasone, floxuridine)
Active, not recruiting
- Colorectal Cancer
- Metastatic Cancer
- FOLFOX regimen
- +7 more
-
New Brunswick, New Jersey
- +1 more
Jul 1, 2022
Potentially Resectable Hepatocellular Carcinoma Trial (FOLFOX-HAIC+Lenvatinib+Envolizumab)
Not yet recruiting
- Potentially Resectable Hepatocellular Carcinoma
- (no location specified)
Nov 16, 2023
Hepatocellular Carcinoma Trial in Tianjin (HAIC, Sintilimab, Bevacizumab Biosimilar)
Recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Jan 16, 2022
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for
Recruiting
- Hepatocellular Carcinoma Non-resectable
- HAIC
- +8 more
-
Quanzhou, Fujian, China
- +1 more
Jan 26, 2023
C-staged Hepatocellular Carcinoma in BCLC Classification Trial in Guangzhou (Hepatic Arterial Infusion combined with Apatinib
Recruiting
- C-staged Hepatocellular Carcinoma in BCLC Classification
- Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 3, 2022